The purpose of this study is to evaluate the safety and performance of the Harpoon Medical TSD-5. The Harpoon device will provide many significant advantages over current surgical interventions including: 1) a small minimally invasive incision, 2) no sternotomy, 3) no cardiopulmonary bypass, 4) no aortic manipulation, 5) a direct path to the valve plane, 6) performed on a beating heart, 7) real-time TEE-guided chordal length adjustment and 8) less complicated procedure that is teachable and adoptable.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Subjects With Procedural Success During the First 30 Days
Timeframe: Procedure through 30 days
Percentage of Subject's With Freedom From Serious Adverse Events (SAE) </= 30 Days
Timeframe: Procedure through 30 days
Subject's Serious Adverse Events (SAE) Through Discharge
Timeframe: Discharge, an average of 8 days post implantation